Facebook link Linked In link You Tube link

Cancer Immunity & Immunotherapy

Organized in collaboration with the Society for Immunotherapy of Cancer (SITC)



Cancer Immunity & Immunotherapy

Wednesday, June 20 at FOCIS 2018
San Francisco Marriott Marquis
San Francisco, CA

You may add Cancer Immunity & Immunotherapy to your FOCIS 2018 registration or attend the course only.


button register 45

Course Directors

Abbas 4 Leisha Emens

Abul K. Abbas, MD
University of California, San Francisco

Leisha A Emens, MD, PhD
Johns Hopkins University

Quick Links

Registration Rates

Rate   One Course     Two Course Package  

button register 45

Regular Member $215 $350  
Regular Non-member $315 $450  
Trainee/Medical Student Member $165 $250  
Trainee/Medical Student Non-member $195 $280  
Industry Member $415 $550  
Industry Non-member $565 $700  

Join FOCIS to take advantage of the reduced course registration rate and much more!


The purpose of this course is to review tumor immunology as the scientific foundation for the current practice of cancer immunotherapy, emphasizing fundamental principles, recent clinical advances, current limitations, and near-term opportunities for further accelerating clinical progress.

Target Audience

This course is designed for translational researchers and scientists, practicing clinicians, trainees, and indviduals in biotechnology and pharmaceutical companies interested in immuno-oncology and the development of immunotherapies for cancer.

Course Objectives

Completion of this course, will allow participants to:

  • Describe mechanisms of the immune response against cancer cells and how these responses are regulated during cancer development and progression.
  • Describe the principles underlying chimeric antigen receptor-transduced T cells (CAR-T cells) and T cell receptor (TCR)-transduced T cells and their efficacy in the treatment of leukemias and other cancers.
  • Appreciate the potential opportunities and limitations of utilizing CAR-T cells for treating solid tumors and understand the development of second generation CARs.
  • Understand the biology of immune checkpoint pathways and checkpoint blockade therapy for solid tumors, the development of biomarkers to predict therapeutic responses, and the potential for combination therapies.
  • Describe the unique adverse event profile associated with immune checkpoint blockade and CAR-T cell therapy, and clinical strategies for managing those immune-related toxicities.
  • Understand the potential of emerging strategies for cancer immonotherapy.

Course Agenda 

Wednesday, June 20
8:00am - 9:00am The Mechanistic Basis of Cancer Immunotherapy- Leisha Emens, MD, PhD
9:00am - 9:40am Manipulating the Tumor Environment (DCs, Tregs, others) - Max Krummel, PhD
9:40am - 10:00am Break
10:00am-10:40am CAR-T Cell Therapy: Principles and Current Practices - Crystal Mackall, MD
10:40am - 11:20am CAR-T Cell Therapy: Next Generation CARs Toxicities, Challenges and Prospects - Crystal Mackall, MD
11:20am-12:00pm T-cell Receptor Transduced T-cells - Cassian Yee, MD
12:00pm - 12:45pm Lunch with Faculty
12:45pm - 1:30pm Checkpoint Blockade Therapy: Current Status & Biomarkers - Ira Mellman, PhD
1:30pm - 2:10pm Next Generation Checkpoint and Combination Therapies - Ira Mellman, PhD
2:10pm - 2:50pm Focus on Engineered Antibodies (bispecific antibodies, antibody-cytokine fusions and other types of armed antibody products) - Dario Neri, PhD
2:50pm - 3:30pm Immune-Related Toxicity: Mechanisms and Management - Kevan Herold, MD
3:30pm - 3:45pm Break
3:45pm - 4:30pm Vaccination Strategies, Identification of Neoantigens - Lisa Butterfield, PhD
4:30pm - 5:00pm Future Prospects and Challenges in Cancer Immunotherapy - Jeffrey Bluestone, PhD

Continuing Medical Education (CME)
FOCIS will not offer CME credit for any course or session at FOCIS 2018. Certificates of attendance will be available upon request.